Financial Snapshot

Revenue
$9.210M
TTM
Gross Margin
84.83%
TTM
Net Earnings
-$84.99M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
134.06%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
-$34.05M
Q3 2024
Cash
Q3 2024
P/E
-1.268
Nov 29, 2024 EST
Free Cash Flow
-$59.62M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $5.124M $9.032M $12.00M $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -43.27% -24.73%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $5.124M $9.032M $12.00M $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue $500.0K $725.0K
Gross Profit $4.624M $8.307M
Gross Profit Margin 90.24% 91.97%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Selling, General & Admin $47.31M $17.41M $26.98M $24.51M $14.64M $9.050M $730.0K $200.0K
YoY Change 171.79% -35.49% 10.07% 67.42% 61.77% 1139.73% 265.0%
% of Gross Profit 1023.03% 209.52%
Research & Development $20.30M $12.20M $15.93M $15.67M $15.44M $12.83M $3.730M $1.710M
YoY Change 66.38% -23.42% 1.63% 1.54% 20.35% 243.86% 118.13%
% of Gross Profit 438.91% 146.84%
Depreciation & Amortization $500.0K $454.0K $244.0K $43.00K $64.20K $20.30K
YoY Change 10.13% 86.07% 467.44% -33.02% 216.26%
% of Gross Profit 10.81% 5.47%
Operating Expenses $70.88M $30.33M $42.91M $40.18M $30.08M $21.88M $4.457M $1.910M
YoY Change 133.72% -29.32% 6.79% 33.58% 37.49% 390.87% 133.35%
Operating Profit -$65.76M -$21.30M -$30.91M -$40.18M -$30.08M -$21.88M -$4.457M
YoY Change 208.79% -31.1% -23.08% 33.58% 37.49% 390.87%

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Interest Expense $3.962M $2.172M $4.295M $3.034M $1.880M $1.230M $0.00 $0.00
YoY Change 82.41% -49.43% 41.56% 61.38% 52.85%
% of Operating Profit
Other Income/Expense, Net -$1.236M -$3.191M -$4.172M -$2.513M $1.873M $1.230M -$2.000K
YoY Change -61.27% -23.51% 66.02% -234.17% 52.28% -61600.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Pretax Income -$67.00M -$24.49M -$35.08M -$42.69M -$28.21M -$20.65M -$4.460M -$1.910M
YoY Change 173.59% -30.2% -17.83% 51.33% 36.61% 363.0% 133.51%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$67.00M -$24.49M -$35.08M -$42.69M -$28.21M -$20.65M -$4.459M -$1.910M
YoY Change 173.59% -30.2% -17.83% 51.36% 36.61% 363.06% 133.46%
Net Earnings / Revenue -1307.47% -271.11% -292.33%
Basic Earnings Per Share -$1.48 -$0.72 -$1.30
Diluted Earnings Per Share -$1.48 -$0.72 -$1.297M -$1.708M -$1.133M -$800.1K -$178.8K -$76.55K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

No data

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Cash & Short-Term Investments $69.55M $34.27M $70.35M $65.47M $62.02M $89.81M $8.660M $530.0K
YoY Change 102.92% -51.28% 7.46% 5.56% -30.94% 937.07% 1533.96%
Cash & Equivalents $69.55M $34.27M $15.75M $10.69M $9.240M $10.27M $8.660M $530.0K
Short-Term Investments $0.00 $54.60M $54.78M $52.78M $79.54M
Other Short-Term Assets $2.545M $4.355M $3.974M $2.180M $2.970M $1.340M $420.0K $20.00K
YoY Change -41.56% 9.59% 82.29% -26.6% 121.64% 219.05% 2000.0%
Inventory $1.022M
Prepaid Expenses
Receivables $4.248M
Other Receivables $168.0K
Total Short-Term Assets $77.53M $39.12M $74.33M $67.65M $64.98M $91.15M $9.080M $540.0K
YoY Change 98.21% -47.38% 9.87% 4.11% -28.71% 903.85% 1581.48%
Property, Plant & Equipment $3.615M $5.330M $5.502M $4.940M $2.200M $260.0K $0.00
YoY Change -32.18% -3.13% 11.38% 124.55% 746.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $452.0K $276.0K $295.0K $1.570M $1.240M $500.0K $0.00
YoY Change 63.77% -6.44% -81.21% 26.61% 148.0%
Total Long-Term Assets $4.067M $5.606M $5.797M $6.500M $3.440M $760.0K $0.00 $0.00
YoY Change -27.45% -3.29% -10.82% 88.95% 352.63%
Total Assets $81.60M $44.72M $80.13M $74.15M $68.42M $91.91M $9.080M $540.0K
YoY Change
Accounts Payable $2.464M $507.0K $845.0K $350.0K $1.190M $920.0K $150.0K $70.00K
YoY Change 386.0% -40.0% 141.43% -70.59% 29.35% 513.33% 114.29%
Accrued Expenses $14.18M $2.952M $3.511M $3.310M $2.170M $1.520M $450.0K $320.0K
YoY Change 380.49% -15.92% 6.07% 52.53% 42.76% 237.78% 40.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $376.0K $0.00 $41.70M $35.32M
YoY Change -100.0% 18.06%
Total Short-Term Liabilities $17.02M $3.459M $46.06M $39.48M $3.350M $2.480M $620.0K $420.0K
YoY Change 392.17% -92.49% 16.65% 1078.51% 35.08% 300.0% 47.62%
Long-Term Debt $43.90M $0.00 $16.00K $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $910.0K $1.229M $1.449M $1.690M $60.00K
YoY Change -25.96% -15.18% -14.26% 2716.67%
Total Long-Term Liabilities $44.81M $1.229M $1.465M $1.690M $60.00K $0.00 $0.00 $0.00
YoY Change 3546.05% -16.11% -13.31% 2716.67%
Total Liabilities $61.83M $4.688M $47.52M $41.17M $3.410M $2.480M $620.0K $420.0K
YoY Change 1218.98% -90.13% 15.42% 1107.33% 37.5% 300.0% 47.62%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Basic Shares Outstanding 45.34M 34.16M 27.04M
Diluted Shares Outstanding 45.34M 34.16M 27.04M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $107.77 Million

About Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 100 full-time employees. The company went IPO on 2018-06-15. The firm is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Industry: Pharmaceutical Preparations Peers: SEELOS THERAPEUTICS, INC. Athira Pharma, Inc. CorMedix Inc. DURECT CORP Ikena Oncology, Inc. JOHNSON & JOHNSON Paratek Pharmaceuticals, Inc. scPharmaceuticals Inc. TFF Pharmaceuticals, Inc.